Mercedes Robles-Diaz

Dr. Mercedes Robles-Diaz


Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2014 in Gastroenterology
Verified
Journal Article
Closed access
MRMercedes Robles-Diaz
Mercedes Robles-Diaz
Mª Isabel LucenaMª Isabel Lucena
Mª Isabel Lucena
NKNeil Kaplowitz
Neil Kaplowitz
CSCamilla Stephens
Camilla Stephens
IMInmaculada Medina–Cáliz
Inmaculada Medina–Cáliz
RARaul J. Andrade
Raul J. Andrade

28 May 2009 in Hepatology
Verified
Journal Article
Open access
PDF file
Mª Isabel LucenaMª Isabel Lucena
Mª Isabel Lucena
RARaul J. Andrade
Raul J. Andrade
NKNeil Kaplowitz
Neil Kaplowitz
MGMiren Garcia-Cortes
Miren Garcia-Cortes
MFM. Carmen Fernández
M. Carmen Fernández
SDSpanish Group for the Study of Drug-Induced Liver Disease
Spanish Group for the Study of Drug-Induced Liver Disease
Increased age and female sex are suggested risk factors for drug-induced hepatotoxicity (DILI). We studied the influence of these variables on the propensity to develop DILI, as well as its clinical expression and outcome. All cases of DILI submitted to the Spanish Registry between April 1994 and August 2007 were analyzed. Six hundred three DILI cases (310 men; mean age, 54 years) showed a similar sex distribution, reaching two peaks in the 40- to 49-year-old and 60- to 69-year-old age groups. No cases were recorded in the 20- to 29-year-old group. Patients aged ≥60 years accounted for 46% of the cases, with a male predominance (158 males, 118 females; P= 0.009), as opposed to younger patients. Older age was independently associated with cholestatic type of injury (odds ratio for an age interval for 1 year: 1.024 [95% confidence interval: 1.010-1.038]; male/female ratio, 1:2;P = 0.001) and younger age with hepatocellular damage (odds ratio: 0.983 [95% confidence interval: 0.972-0.994]; female/male ratio, 1:2;P = 0.002). In the mixed group, no age effect was evident. Outcome with fulminant liver failure/liver transplantation was more frequently encountered in women (P < 0.01). Conclusion:Neither older age nor female sex are predisposing factors to overall DILI. However, older age is a determinant for cholestatic damage with a male predominance, whereas younger age is associated with cytolytic damage and a female overrepresentation. Women distinctly exhibit the worst outcome. Knowledge of these phenotypic associations could guide differential diagnosis and attribution of causality in DILI. (HEPATOLOGY 2009;49:2001–2009.)

8 May 2023 in Journal of Hepatology
Verified
Journal Article
Open access
RARaul J. Andrade
Raul J. Andrade
GAGuruprasad Aithal
Guruprasad Aithal
NBNanne De Boer
Nanne De Boer
RLRodrigo Liberal
Rodrigo Liberal
Alexander GerbesAlexander Gerbes
Alexander Gerbes
EBEinar S. Björnsson
Einar S. Björnsson
Drug-induced liver injury (DILI) can mimic almost all other liver disorders. A phenotype increasingly ascribed to drugs is autoimmune-like hepatitis (ALH). This article summarises the major topics discussed at a joint International Conference held between the Drug-Induced Liver Injury consortium and the International Autoimmune Hepatitis Group. DI-ALH is a liver injury with laboratory and/or histological features that may be indistinguishable from those of autoimmune hepatitis (AIH). Previous studies have revealed that patients with DI-ALH and those with idiopathic AIH have very similar clinical, biochemical, immunological and histological features. Differentiating DI-ALH from AIH is important as patients with DI-ALH rarely require long-term immunosuppression and the condition often resolves spontaneously after withdrawal of the implicated drug, whereas patients with AIH mostly require long-term immunosuppression. Therefore, revision of the diagnosis on long-term follow-up may be necessary in some cases. More than 40 different drugs including nitrofurantoin, methyldopa, hydralazine, minocycline, infliximab, herbal and dietary supplements (such as Khat and Tinospora cordifolia) have been implicated in DI-ALH. Understanding of DI-ALH is limited by the lack of specific markers of the disease that could allow for a precise diagnosis, while there is similarly no single feature which is diagnostic of AIH. We propose a management algorithm for patients with liver injury and an autoimmune phenotype. There is an urgent need to prospectively evaluate patients with DI-ALH systematically to enable definitive characterisation of this condition.

1 September 2016 in Journal of Hepatology
Verified
Journal Article
Closed access
IMInmaculada Medina-Caliz
Inmaculada Medina-Caliz
MRMercedes Robles-Diaz
Mercedes Robles-Diaz
BGBeatriz Garcia-Muñoz
Beatriz Garcia-Muñoz
CSCamilla Stephens
Camilla Stephens
AOAida Ortega-Alonso
Aida Ortega-Alonso
RARaul J. Andrade
Raul J. Andrade

Verified
Journal Article
Open access
PDF file
MGMiren Garcia-Cortes
Miren Garcia-Cortes
MRMercedes Robles-Diaz
Mercedes Robles-Diaz
AOAida Ortega-Alonso
Aida Ortega-Alonso
IMInmaculada Medina-Caliz
Inmaculada Medina-Caliz
RARaul J. Andrade
Raul J. Andrade
Dietary supplements (DS) are extensively consumed worldwide despite unproven efficacy. The true incidence of DS-induced liver injury (DSILI) is unknown but is probably under-diagnosed due to the general belief of safety of these products. Reported cases of herbals and DS-induced liver injury are increasing worldwide. The aim of this manuscript is to report a tabular listing with a description of DS associated with hepatotoxicity as well as review the phenotype and severity of DSILI. Natural remedies related to hepatotoxicity can be divided into herbal product-induced liver injury and DS-induced liver injury. In this article, we describe different DS associated with liver injury, some of them manufactured DS containing several ingredients (Herbalife™ products, Hydroxycut™, LipoKinetix™, UCP-1 and OxyELITE™) while others have a single ingredient (green tea extract, linoleic acid, usnic acid, 1,3-Dimethylamylamine, vitamin A, Garcinia cambogia and ma huang). Additional DS containing some of the aforementioned ingredients implicated in liver injury are also covered. We have also included illicit androgenic anabolic steroids for bodybuilding in this work, as they are frequently sold under the denomination of DS despite being conventional drugs.

13 November 2014 in Alimentary Pharmacology & Therapeutics
Verified
Journal Article
Open access
PDF file
MRMercedes Robles-Diaz
Mercedes Robles-Diaz
AGAndres Gonzalez-Jimenez
Andres Gonzalez-Jimenez
IMI. Medina‐Caliz
I. Medina‐Caliz
CSC. Stephens
C. Stephens
MGMiren Garcia-Cortes
Miren Garcia-Cortes
TNthe SLatinDILI Network
the SLatinDILI Network
Summary: Background: We have observed an increase in hepatotoxicity (DILI) reporting related to the use of anabolic androgenic steroids (AAS) for bodybuilding.Aim: To characterise phenotype presentation, outcome and severity of AAS DILI.Methods: Data on 25 cases of AAS DILI reported to the Spanish (20) and Latin‐American (5) DILI Registries were collated and compared with previously published cases.Results: AAS DILI increased from representing less than 1% of the total cases in the Spanish DILI Registry in the period 2001–2009 to 8% in 2010–2013. Young men (mean age 32 years), requiring hospitalisation, hepatocellular injury and jaundice were predominating features among the AAS cases. AAS DILI caused significantly higher bilirubin values independent of type of damage when compared to other drug classes (P = 0.001). Furthermore, the cholestatic AAS cases presented significantly higher mean peak bilirubin (P = 0.029) and serum creatinine values (P = 0.0002), compared to the hepatocellular cases. In a logistic regression model, the interaction between peak bilirubin values and cholestatic damage was associated with the development of AAS‐induced acute kidney impairment (AKI) [OR 1.26 (95% CI: 1.035–1.526); P = 0.021], with 21.5 ×ULN being the best bilirubin cut‐off point for predicting AKI risk (AUCROC 0.92). No fatalities occurred.Conclusions: Illicit recreational AAS use is a growing cause of reported DILI that can lead to severe hepatic and renal injury. AAS DILI is associated with a distinct phenotype, characterised by considerable bilirubin elevations independent of type of damage. Although hepatocellular injury predominates, acute kidney injury develops in cholestatic cases with pronounced jaundice.